Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type diabetes.

被引：0
|
作者：
He, YL [1 ]
Balch, A [1 ]
Campestrini, J [1 ]
Rivere, GJ [1 ]
Serra, D [1 ]
Prasad, P [1 ]
Ligueros-Saylan, M [1 ]
机构：
[1] Novartis Pharmaceut, NIBR, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2005年 / 77卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P56 / P56
页数：1
相关论文
共 50 条
  • [21] Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
    Ristic, S
    Byiers, S
    Foley, J
    Holmes, D
    DIABETES OBESITY & METABOLISM, 2005, 7 (06): : 692 - 698
  • [22] Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin
    Wright, D. Hamish
    Herman, Gary A.
    Maes, Andrea
    Liu, Qi
    Johnson-Levonas, Amy O.
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (10): : 1157 - 1167
  • [23] Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
    Hideo Otsuki
    Takeo Kosaka
    Kenzo Nakamura
    Fumihiko Shimomura
    Yoshitaka Kuwahara
    Takuji Tsukamoto
    International Urology and Nephrology, 2014, 46 : 427 - 432
  • [24] Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
    Otsuki, Hideo
    Kosaka, Takeo
    Nakamura, Kenzo
    Shimomura, Fumihiko
    Kuwahara, Yoshitaka
    Tsukamoto, Takuji
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (02) : 427 - 432
  • [25] DPP-4 Inhibitor Treatment in Chinese Type 2 Diabetes Patients: A Meta-Analysis
    Cai, Xiaoling
    Gao, Xueying
    Yang, Wenjia
    Chen, Yifei
    Zhou, Lingli
    Zhang, Simin
    Han, Xueyao
    Ji, Linong
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (12) : 784 - 793
  • [26] Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes
    Takatori, Shingo
    Hamada, Yukina
    Tanaka, Akihiro
    Akiyama, Shinji
    Namba, Hiroyuki
    Tanaka, Mamoru
    Kawasaki, Hiromu
    Araki, Hiroaki
    CLINICAL THERAPEUTICS, 2016, 38 (02) : 398 - 403
  • [27] The Effect of DPP-4 Inhibitor, Alogliptin, on Bone Metabolism in Patients With Type 2 Diabetes Mellitus
    Yamauchi, Yuichiro
    Tunekawa, Shin
    Seino, Yusuke
    Uenishi, Eita
    Okawa, Tetuji
    Fujiya, Atushi
    Ishikawa, Kouta
    Ogata, Hidetada
    Iida, Atushi
    Banno, Ryoichi
    Arima, Hiroshi
    Hamada, Yoji
    Oiso, Yutaka
    DIABETES, 2013, 62 : A276 - A277
  • [28] Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy
    Groop, P. -H.
    Cooper, M.
    Perkovic, V.
    Emser, A.
    Seck, T.
    von Eynatten, M.
    Woerle, H. -J.
    DIABETOLOGIA, 2012, 55 : S20 - S21
  • [29] DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment
    Momir Mikov
    Nebojša Pavlović
    Bojan Stanimirov
    Maja Đanić
    Svetlana Goločorbin-Kon
    Karmen Stankov
    Hani Al-Salami
    European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 1 - 14
  • [30] DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment
    Mikov, Momir
    Pavlovic, Nebojsa
    Stanimirov, Bojan
    Danic, Maja
    Golocorbin-Kon, Svetlana
    Stankov, Karmen
    Al-Salami, Hani
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45 (01) : 1 - 14
12345